Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Gastrointestinal 1

Conditions

Rectal Neoplasms 1Mesothelioma 1Lung Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1034Carboplatin 973Paclitaxel 942Gemcitabine 799Cisplatin 759Docetaxel 699Bevacizumab 637Nivolumab 520Pemetrexed 509Cyclophosphamide 476Capecitabine 475Fluorouracil 425Dexamethasone 410Rituximab 392Oxaliplatin 352Injections 349Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 252Ipilimumab 244Doxorubicin 242Lenalidomide 231Fulvestrant 226fludarabine 221durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × MAC321 × Clear all
NCT00063219 2009-08-21

Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 2 Completed
48 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00063427 2009-08-21

Study Evaluating MAC-321 in Colorectal Cancer

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 2 Completed
45 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00685204 2008-05-28

TL139

Taxolog Inc.

Phase 2 Unknown
90 enrolled
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡